Clinical trials: Newly Diagnosed
Multiple Myeloma
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma…
- Trial name
- NCT05827016
- Testing
- Iberdomide, Lenalidomide
- Where
- 269 sites in United States, Argentina and 32 more
- Volunteers
- 1,230 people
- Sponsor
- Bristol-Myers Squibb
Hematoma, Subdural, Chronic
Preventing Recurrences of Chronic Subdural Hematoma in Adult Patients by Middle Meningeal Artery Embolization
Patients with a chronic subdural hematoma (cSDH), that is, a blood accumulation between two meninges developing over a long period of time, often have recurrent bleedings after an initial operation.
- Trial name
- MEMBRANE (NCT05327933)
- Testing
- Surgery plus endovascular MMA embolization, Surgery alone
- Where
- Germany
- Volunteers
- 154 people
- Sponsor
- Unfallkrankenhaus Berlin
Breast Cancer Stage, Insulin Resistance
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer
Breast cancer is one of the most common malignancies in women globally, with ~1.4 million new cases diagnosed annually Breast cancer is one of the leading causes of cancer-related morbidity and mortality among women worldwide.
- Conditions
- Breast Cancer Stage, Insulin Resistance, Racial Bias
- Trial name
- METBC (NCT04741204)
- Testing
- Metformin Extended Release Oral Tablet
- Where
- United States
- Sponsor
- Woman's
Leukemia
S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PSC 833 may help chemotherapy drugs kill more cancer cells by making them more sensitive to the drugs.
- Trial name
- NCT00004217
- Testing
- filgrastim, sargramostim, cytarabine
- Where
- 90 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- SWOG Cancer Research Network
Germ Cell Tumors
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
The purpose of this study is to learn about the safety and effectiveness of two different drug combinations in patients who have intermediate- and poor-risk germ cell tumors (GCT).
- Trial name
- NCT01873326
- Testing
- Paclitaxel, Ifosfamide, Cisplatin
- Where
- 13 sites in United States
- Volunteers
- 92 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Spondyloarthropathy and Sacroilitis
Added Value of Diffusion Weighted MRI in Evaluation of Sacroiliitis in Newly Diagnosed Patients of Spondyloarthropathy.
Spondyloarthropathy encompasses a group of chronic immune-mediated rheumatic inflammatory diseases characterized by axial joint inflammation, peripheral arthritis, enthesitis, dactylitis and extra-articular features.
- Trial name
- NCT05655533
- Testing
- Magnetic resonance Imaging scanners of sacroiliac joints.
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assiut University
Blood Stream Infection, Gut Microbiota
Application of Nanopore Sequencing in Newly Diagnosed Acute Myeloid Leukemia Patients With Bloodstream Infection
Acute myeloid leukemia (AML) patients are prone to blood stream infection (BSI) due to bone marrow suppression, oral and gastrointestinal mucositis, endovascular tubes, and the application of a large number of broad-spectrum…
- Conditions
- Blood Stream Infection, Gut Microbiota, Acute Myeloid Leukemia
- Trial name
- NCT05016752
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Newly Diagnosed Multiple Myeloma
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III trials in MM patients.
- Trial name
- NCT03948035
- Testing
- Elotuzumab, Carfilzomib, Lenalidomide
- Where
- 56 sites in Austria, Germany
- Volunteers
- 576 people
- Sponsor
- Wuerzburg University Hospital
Lymphoma, Large B-Cell, Diffuse
R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL
This is a randomized, open-label, multi-center, phase 3 study evaluating the efficacy of R-ACVBP and DA-EPOCH-R in patients with newly diagnosed non-germinal b-cell-like diffuse large B-cell lymphoma
- Trial name
- NCT03018626
- Testing
- Rituximab, Etoposide, Doxorubicin
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Chronic Myeloid Leukemia in Chronic Phase
Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China
This is a multicenter, non-interventional real-world study designed to assess the efficacy and safety of asciminib in patients with newly diagnosed CML.The study uses a prospective data collection design to gather baseline, pre…
- Trial name
- ASC4CN (NCT07375355)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases
The goal of this retrospective real-world study is to evaluate the effectiveness and safety of first-line osimertinib combined with early intracranial stereotactic radiotherapy (SRT) in patients with EGFR-mutant non-small cell…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Osimertinib, Stereotactic Radiation
- Trial name
- NCT07491211
- Testing
- Osimertinib, intracranial stereotactic radiotherapy
- Where
- 3 sites in China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Craniopharyngioma, Child, Craniopharyngioma
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
- Conditions
- Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
- Trial name
- PNOC029 (NCT05465174)
- Testing
- Tovorafenib
- Where
- 20 sites in United States, Australia
- Volunteers
- 57 people
- Sponsor
- Sabine Mueller, MD, PhD
Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma
Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
Phase I trial to study the effectiveness of paclitaxel, cisplatin, and topotecan with or without filgrastim in treating patients who have newly diagnosed stage III or stage IV epithelial ovarian cancer.
- Conditions
- Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma
- Trial name
- NCT00002913
- Testing
- paclitaxel, cisplatin, topotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myelogenous Leukemia
Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
The purpose of this study is to evaluate and compare the side effects and anti-leukemic benefits of imatinib with those of interferon and Ara-C for patients who have chronic myeloid leukemia (CML) in the chronic phase.
- Trial name
- NCT00333840
- Testing
- imatinib mesilate, interferon-alpha (INF-a), cytarabine (ARA-C)
- Where
- 163 sites in United States, Australia and 14 more
- Volunteers
- 1,106 people
- Sponsor
- Novartis Pharmaceuticals
Benign Neoplasms, Brain, Brain Cancer
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
The purpose of this study is to determine the safety and utility of 5-aminolevulinic acid (ALA) for identifying your tumor during surgery. 5-ALA is not FDA approved at this time.
- Conditions
- Benign Neoplasms, Brain, Brain Cancer, Brain Neoplasms, Benign, Brain Neoplasms, Malignant
- Trial name
- NCT01445691
- Testing
- 5-ALA (Gliolan)
- Where
- 6 sites in United States
- Sponsor
- Constantinos Hadjipanayis
Multiple Myeloma
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
- Trial name
- MagnetisMM-6 (NCT05623020)
- Testing
- Elranatamab, Daratumumab, Lenalidomide
- Where
- 180 sites in United States, Argentina and 23 more
- Volunteers
- 1,060 people
- Sponsor
- Pfizer
Epilepsy, Complex Partial
Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy
The purpose of this study is to determine whether zonisamide alone is effective as a treatment for epilepsy in newly diagnosed cases.
- Trial name
- NCT00056576
- Testing
- Zonisamide
- Where
- 35 sites in United States, Estonia and 3 more
- Volunteers
- 165 people
- Sponsor
- Eisai Inc.
Hodgkin Lymphoma
Brentuximab for Newly Diagnosed Hodgkin Disease
The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).
- Trial name
- NCT02398240
- Testing
- Brentuximab Vedotin, Doxorubicin, Vincristine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mitchell Cairo
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
This randomized phase II trial is studying bicalutamide, goserelin, or leuprolide acetate to see how well they work when given with or without cixutumumab in treating patients with newly diagnosed metastatic prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT01120236
- Testing
- Bicalutamide, Cixutumumab, Goserelin Acetate
- Where
- 170 sites in United States, Canada
- Volunteers
- 211 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Diagnosis
Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients
In this study will be randomised before induction treatment either to receive two courses of melphalan 200 mg/m2 (MEL200) or two courses of melphalan 100 mg/m2 (MEL100). Informed consent will be obtained upon enrolment.
- Trial name
- NCT00950768
- Testing
- Autologous transplantation
- Volunteers
- 298 people
- Sponsor
- Azienda Ospedaliera San Giovanni Battista